We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Universal Health (UHS) Q2 Earnings In-Line, Revenues Beat
Read MoreHide Full Article
Universal Health Services Inc. (UHS - Free Report) reported second-quarter 2016 adjusted earnings of $1.94 per share, in-line with the Zacks Consensus Estimate. Meanwhile, earnings improved 4.9% on a year-over-year basis.
The upside was driven by a 6.8% increase in revenues to around $2.43 billion, which was well-ahead of the Zacks Consensus Estimate of $2.27 billion.
Quarter Details
Same facility revenues from acute care hospitals increased 7.4% year over year in the quarter. Adjusted admissions climbed 3.9% while adjusted patient days increased 2.8% from the same quarter last year.
Net revenue per adjusted admission inched up 1.3%, while net revenue per adjusted patient day was up 2.4%.
Meanwhile, same facility revenues from behavioral hospitals improved 2% in the quarter. Adjusted admissions decreased 0.3% while adjusted patient days increased 0.2% compared to the second quarter of 2015.
Net revenue per adjusted admission inched up 2.4%, while net revenue per adjusted patient day was up 1.9% in the quarter.
Earnings before, lease and rental expense, depreciation and amortization, interest expense, and income taxes ("EBITDAR") contracted 110 basis points (bps) to 18.9%.
Both salaries, wages & benefits and other operating expenses, as a percentage of revenues, increased 60 bps on a year-over-year basis to 46.5% and 24.1%, respectively.
However, supplies expense as a percentage of revenues declined 10 bps to 10.5%. Lease and rental expense as a percentage of revenues remained flat at 1%.
As a result, EBITDA margin contracted 70 bps from the year-ago quarter to 17.5%.
On a same facility basis, operating margin at acute care hospitals decreased 140 bps to 19.1%. Operating margin at behavioral health care facilities contracted 60 bps to 28.1%.
Consolidated operating margin contracted 20 bps to 14.5% in the reported quarter.
Buyback Program
In Feb 2016, Universal Health announced a new share repurchase program worth $400 million, which raised the total authorization to $800 million. During second quarter of 2016, the company repurchased 235,352 shares at an aggregate cost of $29.1 million.
Zacks Rank & Key Picks
Universal Health carries a Zacks Rank #4 (Sell).
Better-ranked stocks in the broader medical sector include MEDNAX Inc (MD - Free Report) , Abiomed Inc and AMN Healthcare Services . Notably, Abiomed and AMN Healthcare services sport a Zacks Rank #1 (Strong Buy), Mednax holds a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Universal Health (UHS) Q2 Earnings In-Line, Revenues Beat
Universal Health Services Inc. (UHS - Free Report) reported second-quarter 2016 adjusted earnings of $1.94 per share, in-line with the Zacks Consensus Estimate. Meanwhile, earnings improved 4.9% on a year-over-year basis.
The upside was driven by a 6.8% increase in revenues to around $2.43 billion, which was well-ahead of the Zacks Consensus Estimate of $2.27 billion.
Quarter Details
Same facility revenues from acute care hospitals increased 7.4% year over year in the quarter. Adjusted admissions climbed 3.9% while adjusted patient days increased 2.8% from the same quarter last year.
Net revenue per adjusted admission inched up 1.3%, while net revenue per adjusted patient day was up 2.4%.
Meanwhile, same facility revenues from behavioral hospitals improved 2% in the quarter. Adjusted admissions decreased 0.3% while adjusted patient days increased 0.2% compared to the second quarter of 2015.
Net revenue per adjusted admission inched up 2.4%, while net revenue per adjusted patient day was up 1.9% in the quarter.
UNIVL HLTH SVCS Price, Consensus and EPS Surprise
UNIVL HLTH SVCS Price, Consensus and EPS Surprise | UNIVL HLTH SVCS Quote
Margin Details
Earnings before, lease and rental expense, depreciation and amortization, interest expense, and income taxes ("EBITDAR") contracted 110 basis points (bps) to 18.9%.
Both salaries, wages & benefits and other operating expenses, as a percentage of revenues, increased 60 bps on a year-over-year basis to 46.5% and 24.1%, respectively.
However, supplies expense as a percentage of revenues declined 10 bps to 10.5%. Lease and rental expense as a percentage of revenues remained flat at 1%.
As a result, EBITDA margin contracted 70 bps from the year-ago quarter to 17.5%.
On a same facility basis, operating margin at acute care hospitals decreased 140 bps to 19.1%. Operating margin at behavioral health care facilities contracted 60 bps to 28.1%.
Consolidated operating margin contracted 20 bps to 14.5% in the reported quarter.
Buyback Program
In Feb 2016, Universal Health announced a new share repurchase program worth $400 million, which raised the total authorization to $800 million. During second quarter of 2016, the company repurchased 235,352 shares at an aggregate cost of $29.1 million.
Zacks Rank & Key Picks
Universal Health carries a Zacks Rank #4 (Sell).
Better-ranked stocks in the broader medical sector include MEDNAX Inc (MD - Free Report) , Abiomed Inc and AMN Healthcare Services . Notably, Abiomed and AMN Healthcare services sport a Zacks Rank #1 (Strong Buy), Mednax holds a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>